CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Neoadjuvant nivolumab with or without platinum-doublet

The earlier, the better? A review of neoadjuvant immunotherapy in

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药

Ahmed Magdy Rabea on LinkedIn: Thank you IASLC for the amazing

MD Anderson Cancer Center on X: “These findings add to evidence

Hidehito HORINOUCHI on X: 🔥CheckMate 77T 🎙️Dr. Tina Cascone

Perioperative Therapy for Resectable Non–Small-Cell Lung Cancer

IJMS, Free Full-Text

JCM, Free Full-Text